TAGRISSO granted FDA breakthrough therapy status in EGFR-mutated lung cancer

This article was originally published here

The Food and Drug Administration’s (FDA) BTD is designed to accelerate the development and regulatory review of potential new medicines that are intended to treat a serious condition

The post TAGRISSO granted FDA breakthrough therapy status in EGFR-mutated lung cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply